Dispensing of Medication to Students Clause Samples

The 'Dispensing of Medication to Students' clause outlines the procedures and requirements for administering medication to students while they are under the care of an educational institution. Typically, this clause specifies who is authorized to dispense medication, the documentation or parental consent required, and the types of medications covered, such as prescription or over-the-counter drugs. Its core function is to ensure student safety and legal compliance by establishing clear guidelines for medication administration, thereby minimizing risks and potential liability for the institution.
Dispensing of Medication to Students. Except in case of emergency no bargaining unit member, other than the Registered Nurse, will be required to administer medication as part of their job duties.
View SourceView Similar (5)
Dispensing of Medication to Students a. No bargaining unit member, other than the Registered Nurse or Certified School Nurse, will be required to administer medication as part of their job duties. b. Any bargaining unit member choosing to voluntarily dispense medication to a student(s) in an emergency, shall be fully indemnified by the Board in the event of a resulting legal action. c. No employee will be required to perform student related services without prior training and authorization by the student’s parent/guardian or physician. Included in the definition of “related services” is assisted feeding (such as tube-feeding), diapering, or other services required by the student’s individualized educational plan. Employees required to perform such related services shall be fully indemnified by the Board when acting within the scope of their employment.
View SourceView Similar (2)
Dispensing of Medication to Students. Minooka 201 Nursing practices and procedures will be governed by Board policy and best practices for school nursing as established within the Illinois Nurse Practice Act and the medication administration section of the Illinois School Code. Except in case of emergency, no bargaining unit member other than the Registered Nurse will be required to administer medication or be responsible for the medicine cabinet key as part of their job duties.
View Source
Dispensing of Medication to Students. Section 1. No teachers, except nurses, shall be required to dispense drugs to students. Section 2. If legal action should be brought against any teacher as a result of Dispensing of Medication to a student by a teacher pursuant to Administrative regulations, the Board shall bear all court costs, legal fees, and judgments against such teacher relating to compensatory damages, and specifically excluding judgments relating to punitive damages from this provision. Provided, however, that the Board shall not be responsible for any of the court costs, legal fees, or judgments of said teacher if the teacher was not authorized to dispense medication or otherwise acted outside the scope of his or her employment with the Board.
View Source

Related to Dispensing of Medication to Students

  • Marketing of Production Except for contracts listed and in effect on the date hereof on Schedule 7.19, and thereafter either disclosed in writing to the Administrative Agent or included in the most recently delivered Reserve Report (with respect to all of which contracts the Borrower represents that it or its Subsidiaries are receiving a price for all production sold thereunder which is computed substantially in accordance with the terms of the relevant contract and are not having deliveries curtailed substantially below the subject Property’s delivery capacity), no material agreements exist which are not cancelable on 60 days notice or less without penalty or detriment for the sale of production from the Borrower’s or its Subsidiaries’ Hydrocarbons (including, without limitation, calls on or other rights to purchase, production, whether or not the same are currently being exercised) that (a) pertain to the sale of production at a fixed price and (b) have a maturity or expiry date of longer than six (6) months from the date hereof.

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Radiation Therapy/Chemotherapy Services This plan covers chemotherapy and radiation services. This plan covers respiratory therapy services. When respiratory services are provided in your home, as part of a home care program, durable medical equipment, supplies, and oxygen are covered as a durable medical equipment service.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.